Form 4: Korro Bio, Inc. Chief Medical Officer Obtains Stock Options
SEC Filing (Form 4)
Olukemi Olugemo, Chief Medical Officer of Korro Bio, Inc., acquired 65,000 stock options on June 3, 2024, at an exercise price of $50.48.
Summary
- Olukemi Olugemo, the Chief Medical Officer of Korro Bio, Inc. (KRRO), filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on June 3, 2024, where Olugemo acquired 65,000 stock options.
- The exercise price for these options is $50.48 per share.
- The options vest as to 25% of the shares on May 13, 2025, and the remaining 75% vest in 36 equal monthly installments thereafter, contingent upon continued service.
- Following the reported transaction, Olugemo directly owns 65,000 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and signals confidence in the company's future, but it doesn't provide concrete financial results.
Positives
- The acquisition of stock options by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule of the options incentivizes the Chief Medical Officer to remain with the company for the long term, aligning her interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with company performance.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies.
- The vesting schedule described is typical, with an initial cliff followed by monthly vesting.
- Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the Chief Medical Officer.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of the stock option grant. |
| 05/13/2025 | Date when 25% of the stock options vest. |
| 06/02/2034 | Expiration date of the stock options. |
| 06/04/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.